Genome Integrity & Epigenetics (Collaborator)
Associate Professor of Experimental Cancer Therapeutics
Investigating post-transcriptional mechanisms that drive cancer behaviour and researching novel cancer therapeutics for patients with advanced malignancies.
Following medical training and subsequent specialist training in Medical Oncology at Addenbrooke’s Hospital in Cambridge and the Royal Marsden Hospital, Sarah was awarded a CRUK Junior Clinician Scientist PhD fellowship in 1999 at Cambridge University and held a Clinical Fellowship at the Institute of Cancer Research’s Drug Development Unit.
She was appointed as Senior Lecturer and Honorary Consultant at Imperial College in 2006 and became Director of Imperial’s Early Cancer Trials Unit and established her laboratory studying the dysregulation of mRNA translation in cancer. She has been chief or principal investigator for a number of national and international clinical studies.
Kapacee ZA. et al, (2020), Medical Oncology, 37
Blagden SP. et al, (2020), Lancet Oncol, 21, 969 - 977
Schwenzer H. et al, (2020), RNA Biol, 1 - 11
Berman AJ. et al, (2020), RNA Biol, 1 - 11
Quality of Life with weekly platinum-based chemotherapy in newly diagnosed Ovarian Cancer: the ICON8 phase III randomised controlled clinical trial
BLAGDEN S. et al, (2020), The Lancet Oncology